DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Christensen B, Micic D, Gibson PR. , et al.
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.
Aliment Pharmacol Ther 2018;
47 (06) 753-762
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.